Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Dillmon, Melissa S., Levit, Laura A. , Moushey, E. Allyn, Alva, Ajjai , Blau, Sibel , Dickson, Natalie R. , Gönen, Mithat , González, Maria Magdalena, Hensold, Jack O. , Hinyard, Leslie , King, Tari A. , Lindsey, Stacie , Magnuson, Allison , Marron, Jonathan M. , Mcaneny, Barbara , McDonnell, Theresa Margaret, Nasso, S, Nowakowski, Grzegorz S. , Oettel, Kurt R., Patel, Manali I. , Patt, Debra A. , Perlmutter, Jane , Pickard, Todd , Rodriguez, Gladys , Rosenberg, Abby R. , Russo, Barry, Szczepanek, Connie M. , Smith, Cardinale B. , Teplinsky, Eleonora , Thota, Ramya , Zoň, Robin , Bourbeau, Brian , Foster, Shelagh E., Grubbs, Stephen, Hagerty, Karen L., Hurley, Patricia A. , Kamin, Deborah Y., Phillips, Jonathan , Schilsky, Richard L. , Burris, Howard A. , Hurley, Patricia , Rosenberg, Abby R , Pennell, Nathan A , Cannon, Timothy Lewis , Diehn, Maximilian , Mileham, Kathryn Finch , Srivastava, Piyush, Traina, Tiffany A , Bruinooge, Suanna S. , Schenkel, Caroline

Mayo Clinic

Journal of Clinical Oncology | December 8, 2020 | Volume: 39 | Issue: 2 | Pages: 155-169

10.1200/jco.20.02953 | PMID 33290128 Get It

This report presents the American Society of Clinical Oncology’s (ASCO’s) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.
Asymmetric caudate hypometabolism in the absence of frontal involvement on FDG‐PET in patients with semantic dementia and behavioral symptoms
Savica, Rodolfo , Radford, Jonathan Graff, Spychalla, Anthony J., Gunter, Jeffrey L. , Lowe, Val J. , Whitwell, Jennifer , Josephs, Keith A. , Choudhury, Parichita , Duffy, Joseph R. , Machulda, Mary M. , Schwarz, Christopher G. , Senjem, Matthew L.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.045393 Get It

AbstractBackgroundAlthough semantic dementia (SMD) presents with language decline, patients often develop behavioral changes. Behavioral symptoms in SMD are attributed to both cortical (orbitofrontal cortex atrophy) and subcortical (nucleus accumbens) degeneration in imaging and neuropathological studies. The caudate nucleus has been implicated in early behavioral changes in some phenotypes of frontotemporal dementia. The objective of this study was to determine whether asymmetric ipsilateral caudate nucleus hypometabolism on [18F]‐fluorodeoxyglucose positron emission tomography (FDG‐PET) is associated with early behavioral changes in the absence of frontal hypometabolism in SMD.MethodFifteen patients with a diagnosis of SMD evaluated by the Neurodegenerative Research Group (NRG) at the Mayo Clinic, Rochester from 2006‐2016, who had FDG‐PET, were included in this study. Clinical data was extracted from the medical records including age at presentation, sex, behavioral symptoms and duration of symptoms. Automated average Z‐scores generated from CortexID (GE Healthcare, WI, USA) using 3D stereotactic surface projections were obtained for the following regions bilaterally: temporal lobes, frontal lobes and caudate nucleus. Patients were categorized as left or right hemisphere lateralized based on the higher temporal lobe Z‐scores. Caudate nucleus and frontal lobe Z‐scores were then compared between the two sides for each patient. Hypometabolism was considered present if Z‐scores were greater than 2.ResultOf our cohort, 9/15 (60%) were females with a median age of 68 at presentation and had 3.5 years symptom duration. 13/15 had at least 1 behavioral symptom at presentation. Eleven patients were considered to have left‐lateralized whereas 4 were right‐lateralized in their temporal lobe hypometabolism. Median Z‐scores were significantly different for ipsilateral and contralateral caudate nuclei at 2.5 and 1.6, respectively (p=0.02, Wilcoxon nonparametric test). Frontal lobe median Z‐scores were 1.2 (ipsilateral) and 0.59 (contralateral) with no statistical difference between two sides (p=0.13).ConclusionIn SMD patients who exhibit behavioral symptoms with no frontal hypometabolism on FDG‐PET, asymmetric caudate nuclei hypometabolism should be explored as a possible imaging marker. This implicates abnormal frontal‐striatal circuitry in the development of behavioral symptoms even in the absence of frontal hypometabolism in early behavioral changes in SMD.
Heterogeneity in longitudinal deterioration of white matter microstructural integrity in the population and its implications for cognitive aging
Przybelski, Scott A. , Graff‐Radford, Jonathan , Lowe, Val J. , Petersen, Ronald C. , Poulakis, Konstantinos , Reid, Robert I. , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Jack, Clifford R. , Westman, Eric , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.042669 Get It

AbstractBackgroundWhite matter (WM) changes are widely seen in the elderly due to aging and pathological processes and have significant impact on cognitive aging. It is critical to understand the heterogeneity and drivers (causes) of the longitudinal deterioration of WM microstructural integrity, especially in a population‐based sample, to provide mechanistic insights into cognitive and brain aging.MethodLeveraging longitudinal diffusion tensor imaging (DTI) data from Mayo Clinic Study of Aging, we assessed whether individuals clustered based on distinct longitudinal fractional anisotropy (FA) trajectories. A total of 533 subjects (487 cognitively unimpaired, 62 with mild cognitive impairment and 4 with dementia diagnosis) aged ≥ 60 years and with at least two DTI scans (125 subjects had at least 3 scans) were included. To identify clusters of individuals with common FA profiles over time, we applied an in‐house longitudinal Bayesian mixed‐effects clustering analysis framework to the imaging data. Age at MRI accounted for the longitudinal component of the model, while sex and APOE4 carrier status were used as fixed effects.ResultWe identified four distinct clusters (Figure 1). We found that most WM tracts decline with age across all clusters but brainstem and association fibers were least likely to decline with aging. APOE4 carriership and amyloid deposition did not differ between the clusters. We found a resilient cluster of individuals (34%) (cluster 1) with better baseline WM and systemic vascular health who had a slower rate of cognitive and WM integrity decline over time. These individuals had highest baseline commissural and association fibers. The resilient group was in contrast to an “at risk” cluster of individuals (16%) (cluster 2) who had lower baseline WM integrity and systemic health and declined the fastest in both WM health and cognition over timeConclusionLongitudinal clustering of WM tracts provided insights into the differential aging of WM in the population which may be unrelated to Alzheimer’s disease pathophysiology. Measuring overall WM health and vulnerable tracts in the elderly can be useful as biomarkers and aid in the identification of “at risk” groups for prevention of future cognitive decline.
Effect of disproportionately enlarged subarachnoid space hydrocephalus (DESH) on cognition
Weigand, Stephen D. , Gunter, Jeffrey L. , Graff‐Radford, Jonathan , Petersen, Ronald C. , Cogswell, Petrice M. , Jones, David T. , Schwarz, Christopher G. , Senjem, Matthew L. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.042304 Get It

AbstractBackgroundDisproportionately enlarged subarachnoid‐space hydrocephalus (DESH), characterized by tight high convexity CSF spaces, ventriculomegaly, and enlarged Sylvian fissures, is thought to be an indirect marker of a CSF dynamics disorder. Although this imaging phenotype was originally described in normal pressure hydrocephalus (NPH), it has since been more widely recognized in the aging population with a prevalence of 6‐7% in the Mayo Clinic Study of Aging (MCSA) 1. The clinical significance of DESH with regards to cognitive decline outside of NPH is not yet well‐defined. The goal of this work is to determine if DESH is associated with risk of cognitive impairment.MethodParticipants in the population‐based MCSA who met the following criteria were included: age ≥ 65 years, 3T MRI, cognitively unimpaired at enrollment, and at least one follow‐up visit. A support vector machine based method to detect the DESH imaging features on T1‐weighted MRI was used to calculate “computational DESH” or CDESH scores2 (Figure 1). Cox proportional hazard models were fit with events defined as progression from cognitively unimpaired to mild cognitive impairment or dementia. Time was defined as years from MCSA enrollment to the first visit with cognitive impairment with censoring at last follow‐up. CDESH was modelled as a spline to allow for non‐linear effects. Covariates included age, sex, education, APOE status, cortical thickness, white matter hyperintensity (WMH) volume, and total intracranial volume.ResultParticipant demographics are summarized in Table 1. The model including the above co‐variates showed a significant CDESH effect (p=0.02) with an approximately 20% greater hazard of progression for a CDESH score of +1 versus −1 (HR 1.2, 95% CI 1.0‐1.4) (Figure 2).ConclusionImaging features of disordered CSF dynamics are an independent predictor of subsequent cognitive decline in the MCSA, among other well‐known factors including age, cortical thickness, and APOE status. Therefore, since DESH contributes to cognitive decline and is present in the general population, identifying individuals with DESH features may be important clinically and also used as a selection stratification variable for clinical trials. References: (1) Graff‐Radford et al doi:10.1212/WNL.0000000000008616; (2) N. Gunter et al doi:10.1016/j.nicl.2018.11.015.
Disrupted brain dynamics across the Alzheimer’s disease spectrum is related to tau accumulation
Graff‐Radford, Jonathan, Gunter, Jeffrey L. , Przybelski, Scott A. , Wiste, Heather J. , Fields, Julie A. , Petersen, Ronald C. , Lowe, Val J. , (ADNI), the Alzheimer's Disease Neuroimaging Initiative, Botha, Hugo , Graff‐Radford, Jonathan , Schwarz, Christopher G. , Senjem, Matthew L. , Vemuri, Prashanthi , Machulda, Mary M. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Jones, David T. , (ADNI), the Alzheimer's Disease Neuroimaging Initiative

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.040583 Get It

AbstractBackgroundRecent evidence has implicated brain networks in the pathophysiology of Alzheimer’s disease (AD). However, the phenotypic variability in AD, inter‐individual differences in tau PET uptake patterns, and dynamic nature of functional connectivity have been relatively neglected. In this talk, I will discuss our recent work linking measures of dynamic brain organization to spatially independent tau PET patterns defined in a phenotypically diverse cohort.MethodsWe identified all Mayo Clinic participants with concurrent amyloid PET (PiB), tau PET (AV1451) and task‐free fMRI (impaired participants were all Aβ+). We used independent component analysis (ICA) to identify spatially independent patterns of tau PET uptake. For the fMRI data, we used a Hidden‐Markov Model (HMM) design to identify distinct patterns of activity/connectivity (‘states’). The ICA and HMM parameters were used to project/segment an independent cohort (ADNI) and subsequent longitudinal timepoints for the Mayo cohort. Multilevel Bayesian regression models were fit in Stan to explore the association between phenotype, component load and brain state.ResultsThe optimal HMM model identified 10 brain states (Figure 1). The optimal ICA decomposition identified 42 tau PET components, of which 13 were potentially related to AD pathobiology (Figure 1). Component loads and brain state dwell time differed between diagnostic groups in both Mayo and ADNI cohorts. One state was much more likely to occur in AD in both cohorts (State 8). Cross‐sectionally, State 8 dwell time was associated with higher tau loads, while higher baseline dwell‐time was predictive of ∆tau in participants with at least 2 timepoints (Figure 2).ConclusionWe found links between dynamics of functional connectivity, tau deposition, and cognitive impairment across the AD spectrum using two different cohorts and longitudinal data. Specifically: 1) our method for characterizing tau PET uptake was able to capture the magnitude and spatial pattern of binding across diverse phenotypes; 2) Our data supports a role for dynamic brain connectivity in cognitive impairment due to Alzheimer’s disease; 3) Dynamic connectivity appears to be directly related to AD pathobiology as measured by tau PET. Incorporating the time‐varying nature of connectivity will be important in future studies of connectome‐based disease progression in AD.
CD33, MEF2C, and SORL1 are associated with variability in macroscale functional brain architecture in AD
Radford, Jonathan Graff, Wiste, Heather J. , Gunter, Jeffrey L. , Petersen, Ronald C. , Lowe, Val J. , Ramanan, Vijay K. , Botha, Hugo , Senjem, Matthew L. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Jones, David T.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.046573 Get It

AbstractBackgroundAlzheimer’s disease (AD) is marked by selective disruptions to anatomically‐distinct brain regions and their connectivity which collectively support cognition. Based on a variation of pattern‐recognition analysis of FDG‐PET images, we previously developed a framework, the global functional state space (GFSS), which captures this macroscale architecture by assigning each individual a series of weightings on 10 independent patterns (eigenbrains=EBs). In this study, we applied the GFSS as a quantitative endophenotype to test whether known AD genetic risk factors were associated with variability in large‐scale neurodynamics represented by the GFSS.MethodThe study sample included 410 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) with evidence of cognitive impairment (CDR‐global>0) and amyloidosis (positive amyloid‐PET). The GFSS was estimated for each individual using the set of 10 EBs to describe global patterns of variation in glucose metabolism. AD genetic risk variants identified in prior large consortium case‐control studies were included for analysis if the variant (or a proxy by linkage disequilibrium r 2>0.7) was assayed on both genotyping platforms used in the sample and if the minor allele frequency exceeded 1%. Genetic associations with the collective set of EBs were tested using multivariate linear regression under a dominant genetic model.ResultSignificant multivariate associations were identified for CD33 (p=7.04x10‐4), MEF2C (p=0.001), and SORL1 (p=0.02). These findings remained significant after covarying for age and sex. The strongest component loadings for CD33 (p=9.09x10‐4; std. β=‐0.16) and MEF2C (p=1.59x10‐4; std. β=‐0.18) were for EB1, with the minor allele in each case associated with a negative axis deviation in the direction of the GFSS area representing episodic memory dysfunction. SORL1 displayed its strongest loading onto EB4 (p=0.03, std. β=‐0.11). The association of APOE ɛ4 with the GFSS was marginally nonsignificant (p=0.09).ConclusionWe identified associations of risk variants in CD33, MEF2C, and SORL1 with differences in patterns of FDG hypometabolism in persons with symptomatic AD. These findings establish the GFSS as a useful endophenotype for genetic analyses, particularly as an avenue toward a mechanistic understanding of how heritable factors may influence inter‐individual variability and syndromic diversity in AD. Further investigation in larger and independent cohorts is warranted.
Utility of ioflupane‐SPECT with multimodal imaging in dementia with Lewy bodies
Miyagawa, Toji , Przybelski, Scott A. , Maltais, Daniela D., Jordan, Lennon, Lesnick, Timothy G. , Chen, Qin , Graff‐Radford, Jonathan , Savica, Rodolfo , Petersen, Ronald C. , Fields, Julie A. , Forsberg, Leah K. , Allen, Laura A., Parisi, Joseph E., Lowe, Val J. , Min, Hoon-Ki Paul , Jones, David T. , Knopman, David S. , Machulda, Mary M. , Murray, Melissa E. , Ferman, Tanis J. , Dickson, Dennis W. , Boeve, Bradley F. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.046375 Get It

AbstractBackgroundMultiple imaging modalities have been individually shown to be useful in diagnosing Dementia with Lewy Bodies (DLB). Reduced striatonigral uptake on ioflupane‐SPECT reflects striatonigral dopamine dysfunction observed in DLB, while other imaging modalities assess different aspects of DLB, which potentially work complementarily when used together. We assessed how well ioflupane‐SPECT differentiates DLB from Alzheimer’s Disease Dementia (ADem) and whether adding another imaging modality to ioflupane‐SPECT would provide additional value.MethodIoflupane‐SPECT, MRI, FDG‐PET, and PiB‐PET were assessed on 35 DLB and 14 ADem patients (including 12 patients with eventual autopsy confirmation). Striatonigral dopamine transporter uptake was evaluated semi‐quantitatively with ioflupane‐SPECT using DaTQUANT software (GE Healthcare) to calculate z‐scores of putamen uptake. Hippocampal volume was calculated with structural MRI, cingulate island sign (CIS) ratio with FDG‐PET, and global cortical PiB retention with PiB‐PET.ResultLower DaTQUANT z‐scores of putamen were observed in DLB patients compared to ADem patients (c‐statistic 0.896, p<0.001). Ioflupane‐SPECT showed higher c‐statistic in differentiating DLB from ADem than hippocampal volume on MRI (c‐statistic 0.718, p=0.034), CIS on FDG‐PET (c‐statistic 0.869, p=0.003), or global cortical PiB retention on PiB‐PET (c‐statistic 0.869, p=0.002), but some overlap between two diagnostic groups was still observed with the single imaging modality. Among these imaging modalities, ioflupane‐SPECT was the only modality correlated with the Unified Parkinson Disease Rating Scale (UPDRS) part III, while only PiB‐PET correlated with Montreal Cognitive Assessment (MoCA) test score. Adding another imaging modality to ioflupane‐SPECT enhanced c‐statistics (+MRI c‐statistic 0.931, p<0.001; +FDG‐PET c‐statistic 0.957, p=0.005; +PiB‐PET c‐statistic 0.955, p=0.007), and ioflupane‐SPECT in combination with both FDG‐PET and PiB‐PET showed the highest c‐statistic of 0.974 (p=0.043).ConclusionIoflupane‐SPECT is an excellent imaging modality to identify DLB by detecting striatonigral dopamine dysfunction which is strongly associated with motor impairment in DLB. Correlative neuroimaging with MRI, FDG‐PET, or PiB‐PET may add small incremental value in differentiation of DLB and ADem. Supported by NIH grants (AG016574, AG006786, AG015866, NS100620, AG062677), grant from GE Healthcare, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Deal Family Foundation, and the Little Family Foundation.
Quantitative susceptibility mapping of substantia nigra in dementia with Lewy bodies
Chen, Qin , Przybelski, Scott A. , Lesnick, Timothy G. , Fields, Julie A. , Gunter, Jeffrey L. , Graff‐Radford, Jonathan , Savica, Rodolfo , Graff‐Radford, Neill R., Petersen, Ronald C. , Boeve, Bradley F. , Arani, Arvin , Senjem, Matthew L. , Jack, Clifford R. , Schwarz, Christopher G. , Knopman, David S. , Ferman, Tanis J. , Graff‐Radford, Neill R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.046236 Get It

AbstractBackgroundNeurodegeneration of the substantia nigra in dementia with Lewy bodies is associated with iron deposition, which increases the magnetic susceptibility of the substantia nigra on MRI. The objective of this study was to measure the magnetic susceptibility of the substantia nigra in patients with dementia with Lewy bodies (DLB) and patients with mild cognitive impairment with at least one core feature of DLB (MCI‐DLB) compared to cognitively unimpaired controls (CU) by quantitative susceptibility mapping (QSM).MethodWe studied clinically diagnosed patients with DLB (n=36), patients with MCI‐DLB (n=16), and age‐, gender‐matched CU (n=104) in a case‐control study. MR images used for QSM were performed on 3T MRI with a multi‐echo (5 echoes) 3D gradient recalled echo sequence with a bipolar‐readout. Three‐dimensional regions of interest (ROIs) of bilateral substantia nigra, based on the DISTAL atlas, were propagated from the Mayo Clinic Adult Lifespan Template (MCALT) to each subject’s T1 image using ANTs nonlinear registration. The mean susceptibility values of the substantia nigra were extracted by aligning each subjects QSM image to their T1 image and corresponding ROIs with a 6 DOF rigid registration.ResultThe mean susceptibility values of the substantia nigra bilaterally was 0.110 ± 0.026 for DLB, 0.099 ± 0.028 for MCI‐DLB and 0.091 ± 0.025 for controls (Figure 1). No difference was found across the mean susceptibility from left, right and combined bilateral substantia nigra. Compared to controls, patients with DLB had higher susceptibility in the substantia nigra (p<0.001). The susceptibility of substantia nigra showed an increasing trend from controls to MCI‐DLB and to DLB (p<0.001). There was no correlation between the Unified Parkinson's Disease Rating Scale (UPDRS) and the mean susceptibility in the substantia nigra in patients with MCI‐DLB and DLB (r=0.03; p=0.82).ConclusionQuantitative susceptibility mapping is sensitive to the increased magnetic susceptibility due to higher iron content in the substantia nigra in DLB. The trend of increasing susceptibility from CU to MCI‐DLB and to DLB suggests that iron deposition in the substantia nigra starts to increase as early as the prodromal stage in DLB and continues to increase as the disease progresses independent of the severity of Parkinsonism.
Genome‐wide association study of tau‐PET: Association of variant near NTNG2 with resistance to tau deposition
Wang, Xuewei K, Przybelski, Scott A. , Pillai, Sheela Kumari Raghavan, Kosel, Matthew , Batzler, Anthony, Radford, Jonathan Graff, Lowe, Val J. , Petersen, Ronald C. , Ramanan, Vijay K. , Knopman, David S. , Mielke, Michelle M. , Jack, Clifford R. , Ross, Owen A. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.044321 Get It

AbstractBackgroundTau deposition is a key biological feature of Alzheimer’s disease (AD) that is closely related to cognitive impairment. However, it remains poorly understood why certain individuals may be more susceptible to tau accumulation while others are more resistant. The recent availability of tau positron emission tomography (tau‐PET) provides an opportunity to test the hypothesis that genetic factors are associated with differential tau deposition.MethodsWe performed a genome‐wide association study (GWAS) of tau‐PET on a sample of 754 individuals over age 50 (mean age 72.4 years, 54.6% men, 87.4% cognitively unimpaired) from the population‐based Mayo Clinic Study of Aging. Following genotyping with the Illumina GSA array and standard quality control, 515,206 single nucleotide polymorphisms (SNPs) were tested for association with entorhinal cortex 18F‐flortaucipir tau‐PET burden using linear regression under an additive genetic model and covarying for age and sex.ResultA genome‐wide significant association was identified for rs75546066, an intergenic SNP on chromosome 9 between MED27 (mediator complex subunit 27) and NTNG2 (netrin G2), with the minor (A) allele associated with lower tau burden (p=2.85 x 10‐8, β=‐0.48). Linkage disequilibrium and public expression quantitative trait loci (eQTL) data suggested a functional relationship between rs75546066 and NTNG2, the latter of which is highly expressed in the brain. In addition to this novel finding, three SNPs within MAPT (microtubule‐associated protein tau) displayed nominal associations to tau‐PET burden, including rs3785883 (p=0.04, β=0.07) which was previously associated with higher cerebrospinal fluid tau in an independent cohort. No associations with tau‐PET burden were identified for the APOE (apolipoprotein E) ɛ4 or ɛ2 alleles or for genotyped SNPs previously associated with AD in large case‐control studies.ConclusionTo our knowledge, this study represents the first reported neuroimaging GWAS of tau pathology. Our findings confirm the association of MAPT with tau burden and nominate the rs75546066‐NTNG2 locus as a novel potential protective influence against tau pathology which warrants further functional characterization. Our data also supports the inference that tau accumulation may have a genetic architecture distinct from APOE and other known AD susceptibility genes, which may have implications for improved risk stratification and therapeutic targeting models.
Utility of DTI as a prognostic biomarker in MCI: Beyond AD biomarkers
Pillai, Sheela Kumari Raghavan, Przybelski, Scott A. , Graff‐Radford, Jonathan , Lesnick, Timothy G. , Zuk, Samantha M., Petersen, Ronald C. , Reid, Robert I. , Knopman, David S. , Machulda, Mary M. , Mielke, Michelle M. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S4 | Pages: No page available

10.1002/alz.039871 Get It

AbstractBackgroundGiven that a proportion of mild cognitive impaired (MCI) individuals are amyloid negative and have cerebrovascular disease (CVD), there is a need for biomarkers that can complement AD biomarkers (amyloid and neurodegeneration) for the prediction of future cognitive decline in MCI. The aim of our study was to determine the utility of diffusion tensor imaging (DTI) as a CVD marker for prediction of future cognitive decline in individuals with MCI in conjunction with amyloidosis and neurodegeneration.MethodWe identified 132 MCI individuals ≥60 years old (55 % were amyloid positive and 59 % were male) from the population based sample of Mayo Clinic Study of Aging (MCSA) who had structural MRI, DTI, amyloid PET, and at least one clinical follow‐up after the imaging at the time of their clinical visit as MCI. All imaging scans were acquired and processed using in house developed protocols and pipelines. We used fractional anisotropy in the genu of corpus callosum (FAGCC), as a CVD marker, education/occupation score as a resilience variable, and global cognitive z‐score as the cognitive outcome. Using mixed effect models for cognitive decline, we evaluated three models to test the prognostic ability of (i) DTI marker alone, (ii) DTI marker and amyloid PET, (iii) DTI marker, amyloid PET, and neurodegeneration (cortical thickness). The final parsimonious models included the significant interactions of potential predictors with time, main effects nested within those interactions, and other significant main effects. Since the adjustment for conventional CVD measures like WMH was important to determine the utility DTI over traditional measures, we further assessed the value of FAGCC in conjunction with white matter hyper intensity (WMH).ResultWe found: i) FAGCC was associated with cognitive decline after adjusting for amyloid PET neurodegeneration (Figure 1 and Table 1) and ii) FAGCC was associated with cognitive decline even after controlling for WMH and WMH was no longer significant after accounting for FAGCC (Table 2).ConclusionDTI has significant utility for prediction of cognitive decline in MCI from population‐based samples and will provide complementary information to AD biomarkers.